Edition:
India

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

661.00GBp
23 Feb 2018
Change (% chg)

-10.00 (-1.49%)
Prev Close
671.00
Open
671.00
Day's High
674.50
Day's Low
659.00
Volume
367,750
Avg. Vol
697,757
52-wk High
784.00
52-wk Low
556.00

Latest Key Developments (Source: Significant Developments)

BTG says Zytiga royalties guidance unchanged after patent setback
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - BTG ::SPOKESMAN SAYS PREVIOUS GUIDANCE ON ZYTIGA ROYALTIES IS UNCHANGED, DESPITE U.S. ADMINISTRATIVE COURT DECISION TO INVALIDATE PATENT.BELIEVES EARLIEST LIKELY U.S. GENERIC ENTRY WOULD BE OCTOBER 2018, WHICH IS ALREADY REFLECTED IN THE CONSENSUS OF ANALYSTS.  Full Article

BTG says CFO Rolf Soderstrom to step down as executive director
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BTG PLC ::THAT AFTER 10 YEARS AS CHIEF FINANCIAL OFFICER (CFO) AT BTG, ROLF SODERSTROM IS TO STEP DOWN AS AN EXECUTIVE DIRECTOR OF COMPANY​.‍INTENDS TO APPOINT DUNCAN KENNEDY TO SUCCEED ROLF AS CFO ON 1 JANUARY 2018​.‍ROLF WILL REMAIN WITH COMPANY UNTIL COMPLETION OF A SMOOTH HANDOVER TO DUNCAN, WHICH IS EXPECTED TO BE CONCLUDED BY 31 MARCH 2018​.  Full Article

BTG H1 ‍adjusted operating profit of 99.1 mln stg vs 78.8 mln stg
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Btg Plc :H1 REVENUE 341.3 MILLION STG.H1 ‍ADJUSTED OPERATING PROFIT OF 99.1 MILLION STG VERSUS 78.8 MILLION STG YEAR AGO​.BTG PLC - ‍FURTHER GROWTH IS EXPECTED IN H2 IN INTERVENTIONAL MEDICINE PRODUCT SALES ​.BTG PLC - ‍PHARMACEUTICALS REVENUES IN H2 WILL REFLECT H1-WEIGHTED SEASONALITY OF CROFAB AND FEWER ANTICIPATED EXPIRY ORDERS FOR DIGIFAB COMPARED WITH H2 2016/17​.‍GROUP'S OVERALL OUTLOOK FOR FULL YEAR TO 31 MARCH 2018 REMAINS UNCHANGED​.  Full Article

BTG's Biocompatibles to settle LC Bead probe for $36 mln
Thursday, 6 Oct 2016 

BTG Plc : Settlement of U.S. investigation into LC Bead . Unit Biocompatibles subsidiary reached a settlement with U.S. government in relation to department of justice's investigation of marketing of LC Bead . Says Biocompatibles has agreed to settle all allegations and consequently to pay a total penalty of $36 mln .Investigation focused on period pre-dating BTG's acquisition of Biocompatibles in January 2011.  Full Article

BTG says received approval from Health Canada for DC Bead Lumi
Thursday, 25 Aug 2016 

BTG PLC : Says received approval from Health Canada for DC Bead Lumi . Says anticipates securing regulatory clearances for additional radiopaque bead products in other markets worldwide .Says look forward to providing DC Bead Lumi to Canadian physicians during second half of 2016.  Full Article

BTG says pretax profit doubles for FY
Tuesday, 17 May 2016 

BTG Plc : FY pretax profit 57.5 million STG versus 26.7 million STG year ago .FY revenue rose 22 percent to 447.5 million STG.  Full Article

Galil medical announces agreement to acquisition by Btg Plc
Friday, 6 May 2016 

Btg Plc :Galil Medical announces agreement to acquisition by Btg Plc.  Full Article

BTG acquires Galil Medical
Friday, 6 May 2016 

BTG Plc : Acquisition . BTG Plc acquires Galil Medical, a leader in cryoablation . Will also pay up to $25.5 mln (£17.6m) in future regulatory and commercial milestone payments in respect of period to 31 December 2018 . BTG expects Galil Medical to be profitable and transaction to be earnings accretive in first full year of ownership. . Will acquire Galil Medical for an initial cash consideration of $84.5 mln (£58.3m) . Acquisition will be funded from BTG's existing cash resources .Evercore Partners International LLP advised BTG on transaction..  Full Article

Photo

U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .